Therefore, efforts to stabilize p53 in cancer cells led to develop novel strategies, including delivering wild type p53 to cancer cells using vectors (29), and inhibition of p53 degradation through impeding Mdm2-p53 interaction (30). Here, MDM2 is linked to cancer.